Children and drugs should not mix — unless, of course, the drugs are prescribed by a doctor. However, as the medicalization, decriminalization and legalization of various substances increases or expands, many believe it may be time to have that conversation with their children because drugs are only becoming more accessible as time passes.
While you may not expose your children to recreational drugs of any kind, not everyone else may be as quick to say no. In fact, children are often surrounded by information about and access to a variety of drugs. Here is some valuable information about psychedelic substances and their use in the various groups, including children, that interact with them.
Through the Eurocentrism view, we learn that because adolescents’ and children’s brains are not fully developed, there is a concern that the ingestion of psychedelics may damage a child’s identity formation as well as brain development. Psychedelics are generally deemed as physiologically safe substances that do not cause addiction or dependence.
Classic psychedelics such as ayahuasca, psilocybin and LSD are currently being studied as they possess properties that are anti-addictive. In principle, consuming psychedelic substances daily causes the body to develop a tolerance to the substances in a short time. This reduces the psychedelic substances’ physiological and psychoactive impacts.
While only a few studies that focus on children and psychedelics have been conducted in a medical setting, researchers concluded in the 1960s that the use of LSD as an autism treatment for children held promise and was considered to be a good treatment for many children. These outcomes were dismissed, however, as the designs of the study that had been used during the period were not as effective or rigorous in comparison with today’s standards.
Yale University recently conducted a double-blind study that investigated the effects of ketamine as a treatment for adolescents who suffered from treatment resistant depression. Additionally, MDMA is on the verge of being approved by the FDA as a post-traumatic stress disorder treatment. Legalizing the substqance may help ease the process of approval for the use of MDMA as a PTSD treatment for adolescents.
It should be noted that a large number of adolescents experiment with psychoactive substances before graduating from high school or coming to maturity. A national survey conducted in 2016 showed that nearly 2 million adolescents in the United states aged 12–17 were users of various illicit drugs at the time of the survey. Implementing the zero-tolerance policy may lead to ill-advised self-initiations that have potential to be both harmful and damaging.
Reforming drug education offers a more effective way to build a space that is nonjudgmental and enables the discussion on drug abuse in ways that encourage its de-stigmatization. This allows conversations on psychedelics and drugs in general to be had between youth and their parents in a way that is both informative and risk minimizing.
The promising findings and regulatory changes being made have allowed a number of companies to delve into the psychedelics and functional mushrooms space. One interesting firm within this sector is Cybin Inc. (NEO: CYBN). The company is specializing in developing medicinal psychedelic products in addition to meeting the needs of the functional mushroom niche.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
